



SCREENING (CS) USING WHOLE EXOME SEQUENCING CS Exome based?

CLINICAL ADVANTAGE

- Allows for testing of **All known** recessive conditions.
- Increases the overall detection rate minimizing the global residual risk.

MATCHING

- Maximizes IVF applications, matching possible with ALL genetic lab tests in the market.
- **Simplifies** competitor CS panel mirroring as no resequencing is required to provide matching information.



• Any upgrade possible at a later date if required.



REANALYSIS

- Exome Sequencing offers added value for future analysis of a given patient.
- Provides analytical possibilities in an adverse event of a newborn with a genetic condition.

CGT CGT CGT Bank Plus Exome WHOLE EXOME SEQUENCING (WES) Methodology **Exclusive Panel for Gamete Donors** Type of panel **Expanded Panel Premium Expanded Panel** ACOG M: 470 genes M: 7 genes M: 1,989 genes 8 Genes F: 72 genes (include 65 X-linked) F: 535 genes (include 65 X-linked) F: 2,054 genes (include 65 X-linked) ~3.800 >30,000 >50,000 Variants Numbers of diseases Up to 75 More than 500 More than 2.200 Estimated 26 ~11% ~55% ~67% carrier rate (%)* Estimated mean of (J 1 1.7 2.7 mutations/individual** 150X 150X 150X Mean depth M/F: CYP21A2, HBA1/2, SMN1 M/F: CYP21A2, HBA1/2, SMN1 M/F: CYP21A2, HBA1/2, SMN1 **Complementary tests** F only: DMD, FMR1, F8 F only: DMD, FMR1, F8 F only: DMD, FMR1, F8 Blood or saliva Blood or saliva Blood or saliva Sample 20 working days 20 working days 20 working days TAT

OUR NEW UNIVERSAL APPROACH TO EXPANDED CARRIER

* In-house data base of 30,000 tests **Estimated mean of positive individuals M: male: F: Female

www.igenomix.com

v.2023





CGT is an advanced genetic test performed before pregnancy that determines the risk of having a child with a genetic disease.

It helps prevent disorders without cure.

